Megalotect (Human Cytomegalovirus Immunoglobulin)

The immunoglobulin preparation contains pooled IgG antibodies that specifically bind to CMV particles. This neutralises the virus, blocks cellular entry, and promotes opsonisation, thereby limiting viral replication and assisting the host’s immune system in clearing the infection.

The dosing regimen for Megalotect is individualized and set by the prescribing clinician based on factors such as the patient’s weight, CMV serostatus, type of transplant, and clinical condition. No fixed dose can be provided without a medical prescription.

Safety data for Megalotect during pregnancy and lactation are limited. The product should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To order Megalotect, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and any necessary import documentation.

Megalotect provides passive immunity through antibodies, whereas antiviral drugs such as ganciclovir or valganciclovir act by inhibiting viral DNA synthesis. Immunoglobulin therapy is often used for prophylaxis or in combination with antivirals to enhance protection, especially in patients who cannot tolerate or have resistance to standard antivirals.

Megalotect must be stored refrigerated at 2‑8 °C. It should be kept in its original container, protected from light, and must not be frozen or shaken. Prior to use, inspect the solution for particulate matter or discoloration and allow it to reach room temperature if required for infusion.

Megalotect is given by intravenous infusion. The infusion rate is determined by the prescribing clinician and may start slowly to monitor for reactions, then be increased as tolerated. Administration should be performed in a setting equipped to manage potential infusion‑related adverse events.

Serious risks include anaphylaxis or severe allergic reactions, hemolysis, acute kidney injury, thromboembolic events, and aseptic meningitis. Patients should be closely observed during infusion, and any signs of severe reaction should prompt immediate medical intervention.

Megalotect is contraindicated in individuals with a known severe IgA deficiency who have anti‑IgA antibodies, as well as in patients with a documented hypersensitivity to human immunoglobulin products. Caution is also advised for patients with uncontrolled renal impairment or active severe infections.